EP 241: The hard-won lessons behind Encoded Therapeutics’ Dravet syndrome gene therapy [Re-run]

Value of the Information & Strength of the Argument

The podcast provides valuable insights into the complexities of gene therapy development, particularly for rare neurological diseases. Rico’s firsthand experience with both successes and failures adds credibility. He argues for the importance of thorough natural history studies and cautious dosing, supported by specific examples. The discussion is well-structured, covering technical aspects and strategic considerations. However, as an expert opinion, it lacks empirical data or peer-reviewed references, relying on anecdotal evidence and personal experience.

Scientific Rigor, Source Quality, Title Accuracy

The podcast demonstrates scientific rigor through Rico’s detailed account of clinical trials and regulatory challenges. He references specific studies and outcomes, such as the XLMTM trial and Encoded’s Dravet syndrome program. The sources cited in the description include Encoded’s website and a press release about clinical data, which are relevant. The title accurately reflects the content, focusing on lessons learned. However, the episode is primarily based on expert opinion rather than published research, limiting its scientific robustness.

The title accurately reflects the content, focusing on lessons learned in gene therapy development for Dravet syndrome.

8/10

The podcast features a Chief Medical Officer with extensive experience in gene therapy, discussing both successes and failures with candor. The content is expert opinion, grounded in clinical trial experience, but lacks peer-reviewed citations or detailed data verification.

• 00:00Intro to The Genetics Podcast
• 01:26Welcome to Salvador and how he became involved in drug development
• 11:28Frustrations and rewards of the genetics field
• 14:25Salvador’s study on gene therapy for patients with X-linked myotubular myopathy (XLMTM)
• 20:12Risk of liver issues in gene therapy trials and attempts to mitigate them
• 24:48Encoded Therapeutics‘ approach to drug discovery and what motivated Salvador to join the team
• 27:49Steps towards therapeutic targeting of gene regulatory elements
• 30:30Advantages of different methods for drug delivery
• 32:57DNA- versus RNA-based therapy
• 35:25Insights from approaches in other fields such as psychiatry
• 37:00Considerations for using natural history studies
• 40:58Expectations and goals for Encoded Therapeutics’ current and upcoming studies
• 43:44Closing remarks

• Encoded Therapeutics — Company website providing background on Encoded's gene therapy programs.
• Encoded Therapeutics Presents New Clinical Data from POLARIS Phase 1/2 Trials of ETX101 Gene Therapy in Dravet Syndrome at the ASGCT 2026 Presidential Symposium — Press release detailing clinical data for ETX101 in Dravet syndrome, mentioned as a recent milestone.

• Encoded Therapeutics — Company website supporting the existence of Encoded's programs.
• Encoded Therapeutics Presents New Clinical Data from POLARIS Phase 1/2 Trials of ETX101 Gene Therapy in Dravet Syndrome at the ASGCT 2026 Presidential Symposium — Press release confirming recent clinical milestones for ETX101.